NasdaqGS:DFTXPharmaceuticals
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)?
Definium Therapeutics, Inc. recently appointed veteran biopharmaceutical executive Roger Adsett to its Board of Directors, effective January 29, 2025, while analysts initiated positive coverage emphasizing its late-stage brain health pipeline, including FDA Breakthrough Therapy Designation for DT120 in generalized anxiety disorder.
Adsett’s extensive track record in global drug launches and building commercial organizations at companies such as Insmed, Shire, and AstraZeneca adds experienced...